Rajeev  Saggar net worth and biography

Rajeev Saggar Biography and Net Worth

Insider of Liquidia

Rajeev Saggar, M.D. joined Liquidia in 2022 where he serves as the company’s Chief Medical Officer. He brings more than 20 years of experience as a practicing pulmonologist to his role at Liquidia where he oversees all aspects of research, clinical development, medical affairs and regulatory affairs. Previously, Rajeev served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across its respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD and COVID-19. Prior to this, he served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix, and as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. Rajeev also served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. He has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Rajeev holds a Doctor of Medicine degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.

What is Rajeev Saggar's net worth?

The estimated net worth of Rajeev Saggar is at least $5.99 million as of November 5th, 2025. Saggar owns 176,549 shares of Liquidia stock worth more than $5,988,542 as of December 4th. This net worth estimate does not reflect any other investments that Saggar may own. Learn More about Rajeev Saggar's net worth.

How old is Rajeev Saggar?

Saggar is currently 50 years old. There are 5 older executives and no younger executives at Liquidia. The oldest executive at Liquidia is Dr. Roger A. Jeffs Ph.D., CEO & Director, who is 62 years old. Learn More on Rajeev Saggar's age.

How do I contact Rajeev Saggar?

The corporate mailing address for Saggar and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Rajeev Saggar's contact information.

Has Rajeev Saggar been buying or selling shares of Liquidia?

Within the last three months, Rajeev Saggar has sold $2,051,992.07 in Liquidia stock. Most recently, Rajeev Saggar sold 71,381 shares of the business's stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a transaction totalling $1,927,287.00. Following the completion of the sale, the insider now directly owns 176,549 shares of the company's stock, valued at $4,766,823. Learn More on Rajeev Saggar's trading history.

Who are Liquidia's active insiders?

Liquidia's insider roster includes Jason Adair (Chief Business Officer), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.

Are insiders buying or selling shares of Liquidia?

In the last year, insiders at the sold shares 52 times. They sold a total of 1,155,124 shares worth more than $29,483,872.80. The most recent insider tranaction occured on December, 1st when General Counsel Russell Schundler sold 1,072 shares worth more than $34,507.68. Insiders at Liquidia own 26.5% of the company. Learn More about insider trades at Liquidia.

Information on this page was last updated on 12/1/2025.

Rajeev Saggar Insider Trading History at Liquidia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/5/2025Sell71,381$27.00$1,927,287.00176,549View SEC Filing Icon  
10/13/2025Sell5,327$23.41$124,705.07247,930View SEC Filing Icon  
8/28/2025Sell20,000$27.85$557,000.00249,727View SEC Filing Icon  
8/28/2025Sell20,000$27.85$557,000.00249,727View SEC Filing Icon  
7/21/2025Sell2,526$14.54$36,728.04268,887View SEC Filing Icon  
7/14/2025Sell5,327$14.28$76,069.56271,413View SEC Filing Icon  
4/21/2025Sell2,450$13.67$33,491.50263,152View SEC Filing Icon  
1/21/2025Sell2,445$13.00$31,785.00267,943View SEC Filing Icon  
1/14/2025Sell6,249$11.78$73,613.22270,388View SEC Filing Icon  
10/18/2024Sell2,526$11.19$28,265.94204,857View SEC Filing Icon  
10/14/2024Sell2,260$11.11$25,108.60207,383View SEC Filing Icon  
7/19/2024Sell1,873$11.13$20,846.49208,329View SEC Filing Icon  
4/19/2024Sell1,649$13.68$22,558.32211,672View SEC Filing Icon  
See Full Table

Rajeev Saggar Buying and Selling Activity at Liquidia

This chart shows Rajeev Saggar's buying and selling at Liquidia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Liquidia Company Overview

Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $33.92
Low: $33.00
High: $34.08

50 Day Range

MA: $26.04
Low: $21.80
High: $33.92

2 Week Range

Now: $33.92
Low: $10.37
High: $34.08

Volume

880,832 shs

Average Volume

1,935,568 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48